GTx-104

aSAH occurs suddenly and is caused by a ruptured aneurysm that bleeds in the subarachnoid space between the brain and skull.

Immediate surgical and pharmacotherapy intervention is key as the condition deteriorates quickly.

Currently, the only SoC is oral nimodipine therapy indicated for up to 21 days.

GTx-104 represents a potential solution to a sizable patient population and a significant market opportunity

~50K

Cases of aSAH annually in the US

~50%

Of affected patients under 60 years old

10-15%

Of aSAH patients die before reaching the hospital

~70%

Death/dependence occurs in admitted patients

~$500M

Total US market

Limits of Current SoC

• Heavy dosing burden due to high first pass metabolism
• Poor hypotension management and frequent dose interruption
• Nasogastric tube delivery in unconscious or dysphagic patients
• Food effects and contraindicated with CYP3A inhibitors
• High pharmacokinetic variability with oral route

As a novel IV formulation of nimodipine, GTx-104 is well positioned to potentially solve these challenges.

Clinical Value

• 100% bioavailable for GTx-104 versus only 13% for oral nimodipine
• Potential for effective hypotension management
• No food effects and reduced DDI
• Reduced drug intake
• Predictable drug concentration

Hospital Value

• Potential for reduced medication error
• Potential for reduced nursing burden
• Potential for reduced rescue therapy use
• Potentially shortened ICU stay
• Joint Commission compliance
• Potentially positive economic impact

Patient Value

• Potentially safer
• Potentially improved outcomes
• Convenient dosing
• Potential for faster recovery
• Potential for reduced disease burden